Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Renal Retention of Microbubbles

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jonathan R. Lindner, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier:
NCT01647464
First received: July 19, 2012
Last updated: April 5, 2014
Last verified: April 2014
  Purpose

Flank pain has been reported with ultrasound (US) contrast agents. The purpose of this study is to determine whether there is retention of ultrasound contrast agents in the renal microcirculation, which has been described in mice.


Condition
- Study Focus: Renal Retention of Lipid Microbubbles

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Renal retention of microbubbles [ Time Frame: 10 min ] [ Designated as safety issue: No ]
    Video intensity in the renal circulation 10 min after completion of a clinically indicated contrast echocardiography study.


Enrollment: 10
Study Start Date: July 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Contrast administration
Patients undergoing contrast-enhanced echo.

Detailed Description:

In this study patients undergoing clinically indicated contrast echocardiography will have renal ultrasound performed 10 minutes after completion of contrast infusion to determine the presence and location of renal retention of lipid microbubbles.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing contrast echocardoigraphy

Criteria

Inclusion Criteria:

  • Undergoing clinically indicated contrast echo
  • adequate renal ultrasound images

Exclusion Criteria:

  • chronic inflammatory disease
  • known kidney disease
  • immunomodulatory therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01647464

Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
  More Information

No publications provided

Responsible Party: Jonathan R. Lindner, MD, Professor of Medicine, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT01647464     History of Changes
Other Study ID Numbers: MBretention
Study First Received: July 19, 2012
Last Updated: April 5, 2014
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on November 19, 2014